Presentation October 11th 2016

Newborn Screening for Duchenne Muscular Dystrophy (DMD)


Duchenne muscular dystrophy is one of the ten most severe and common pediatric genetic diseases and affects an estimated 1 in every 5000 male births. While Duchenne muscular dystrophy is still a 100% fatal disease, the clinical community has demonstrated that immediate identification and early clinical interventions can add years, even decades to an individual’s life span.

In the last year, the therapeutic landscape for our Duchenne community has changed and advanced even further.

In August of 2014, the European Commission granted conditional marketing authorization for PTC Therapeutic’s Translarna™ - known as Ataluren in the United States – for use in the European Union (EU) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients aged five years and older. It is estimated that a nonsense mutation is the cause of Duchenne in approximately 13% of patients, or approximately 2,000 patients in the United States and 2,500 patients in the European Union. This fall, confirmatory trials for another promising therapeutic intervention began for the exon skipping therapy being led by Sarepta Therapeutics in the United States and an Accelerated Approval pathway for review commenced this Spring which could potentially benefit yet another 13% of the Duchenne population whose disease may be modified through a skipping of the targeted exon 51. Similarly, Biomarin began the regulatory process under a rolling new drug application for their exon skipping therapy, which would potentially benefit the same subset of the Duchenne population. By the end of 2015, it is anticipated that as many as 4 product reviews could be underway by the FDA in the U.S. for the treatment of Duchenne.

The presentations are available for educational exchange purposes only. Products mentioned in the presentation may not be available in your country. Please consult your local PerkinElmer representative for the products available in your country
This website stores cookies on your computer. These cookies are used to improve our website and provide more personalised services to you.


To make this site work properly, we sometimes place small data files called cookies on your device. Most big websites do this too.

1. What are cookies?

A cookie is a small text file that a website saves on your computer or mobile device when you visit the site. It enables the website to remember your actions and preferences (such as login, language, font size and other display preferences) over a period of time, so you don’t have to keep re-entering them whenever you come back to the site or browse from one page to another.

2. How do we use cookies?

A number of our pages use cookies to remember your actions and preferences (such as login, language, font size and other display preferences.)

Also, some videos embedded in our pages use a cookie to anonymously gather statistics on how you got there and what videos you visited.

Enabling these cookies is not strictly necessary for the website to work but it will provide you with a better browsing experience. You can delete or block these cookies, but if you do that some features of this site may not work as intended.

The cookie-related information is not used to identify you personally and the pattern data is fully under our control. These cookies are not used for any purpose other than those described here.

3. How to control cookies

You can control and/or delete cookies as you wish – for details, see You can delete all cookies that are already on your computer and you can set most browsers to prevent them from being placed. If you do this, however, you may have to manually adjust some preferences every time you visit a site and some services and functionalities may not work.